Home » Stocks » GBIO

Generation Bio Co. (GBIO)

Stock Price: $32.17 USD 0.00 (0.00%)
Updated Jan 15, 2021 4:00 PM EST - Market closed
After-hours: $31.40 -0.77 (-2.39%) Jan 15, 5:05 PM
Market Cap 1.79B
Revenue (ttm) n/a
Net Income (ttm) n/a
Shares Out 45.47M
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 15
Last Price $32.17
Previous Close $32.17
Change ($) 0.00
Change (%) 0.00%
Day's Open 34.99
Day's Range 31.70 - 35.48
Day's Volume 843,389
52-Week Range 18.07 - 51.61

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Benzinga - 2 days ago

Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason — they believe the stock price will rise and they want to profit from it. So insider bu...

Other stocks mentioned: CAG, ALDX, DMTK, FATE, MRSN, ORI, REVG, RILY, SPT, YORW
GlobeNewsWire - 1 week ago

CAMBRIDGE, Mass., Jan. 11, 2021 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), an innovative genetic medicines company creating a new class of gene therapy, today announced the closing...

GlobeNewsWire - 1 week ago

CAMBRIDGE, Mass., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), an innovative genetic medicines company creating a new class of gene therapy, today announced the pricing...

Zacks Investment Research - 1 week ago

Generation Bio (GBIO) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

GlobeNewsWire - 1 week ago

CAMBRIDGE, Mass., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), an innovative genetic medicines company creating a new class of non-viral gene therapy, announced today t...

GlobeNewsWire - 2 weeks ago

Data confirm delivery of closed-ended DNA to the liver via novel, cell-targeted lipid nanoparticles

Seeking Alpha - 1 month ago

The unicorn IPO parade is set to begin in the week ahead, with DoorDash and Airbnb leading the way. A total of six IPOs and two SPACs are scheduled to raise $7.2 billion.

Other stocks mentioned: ABNB, AI, AZEK, DASH, PCVX, RNA, UCL, VRM
GlobeNewsWire - 2 months ago

On Track to Advance Lead Programs into Pre-Clinical Development in 2021 Supported by Key Leadership Team Appointments On Track to Advance Lead Programs into Pre-Clinical Development in 2021 Su...

GlobeNewsWire - 3 months ago

CAMBRIDGE, Mass., Oct. 05, 2020 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), an innovative genetic medicines company creating a new class of non-viral gene therapy, announced today t...

GlobeNewsWire - 3 months ago

CAMBRIDGE, Mass., Sept. 24, 2020 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), an innovative genetic medicines company creating a new class of non-viral gene therapy, announced toda...

GlobeNewsWire - 5 months ago

CAMBRIDGE, Mass., Aug. 11, 2020 (GLOBE NEWSWIRE) -- Generation Bio Co . (Nasdaq: GBIO), an innovative genetic medicines company creating a new class of non-viral gene therapy, today reporte...

GlobeNewsWire - 5 months ago

CAMBRIDGE, Mass., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Generation Bio Co . (Nasdaq: GBIO), an innovative genetic medicines company creating a new class of non-viral gene therapy, today announc...

GlobeNewsWire - 5 months ago

CAMBRIDGE, Mass., July 22, 2020 (GLOBE NEWSWIRE) -- Generation Bio Co . (Nasdaq: GBIO), an innovative genetic medicines company creating a new class of non-viral gene therapy, today announc...

GlobeNewsWire - 7 months ago

CAMBRIDGE, Mass., June 16, 2020 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), an innovative genetic medicines company creating a new class of gene therapy, today announced the closi...

Market Watch - 7 months ago

Shares of Generation Bio Inc., a biotech that specializes in gene therapy treatments for rare diseases, soared 23% Friday in their trading debut, after the IPO was upsized and priced at $19 a ...

Market Watch - 7 months ago

Generation Bio Inc., a biotech that specializes in gene therapy treatments for rare diseases, priced its upsized initial public offering at $19 a share, the high end of its price range.

GlobeNewsWire - 7 months ago

CAMBRIDGE, Mass., June 11, 2020 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), an innovative genetic medicines company creating a new class of gene therapy, today announced the prici...

About GBIO

Generation Bio, a genetic medicines company, develops gene therapies for the treatment of rare and prevalent diseases. The company is developing a portfolio of programs for rare and prevalent diseases of the liver and retina. It also focuses on the diseases of skeletal muscle, central nervous system, and oncology. The company was formerly known as Torus Therapeutics, Inc. and changed its name to Generation Bio Co. in November 2017. Generation Bio Co. was founded in 2016 and is headquartered in Cambridge, Massachusetts.

Industry
Biotechnology
IPO Date
Jun 12, 2020
CEO
Dr. Cameron Geoffrey McDonough
Stock Exchange
NASDAQ
Ticker Symbol
GBIO
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 4 analysts, the average rating for Generation Bio stock is "Strong Buy." The 12-month stock price forecast is 35.67, which is an increase of 10.88% from the latest price.

Price Target
$35.67
(10.88% upside)
Analyst Consensus: Strong Buy